GSK to partner with Vir for potential Covid-19 treatments, invest $250m

British drugmaker GlaxoSmithKline Plc will invest $250 million in Vir Biotechnology Inc and collaborate to develop potential treatments for COVID-19, the disease caused by the new coronavirus, the companies said on Monday.

Drugmakers across the globe are rushing to develop a treatment or vaccine for the fast-spreading coronavirus that has killed over 68,400 people globally. There are currently no approved treatments for the disease.

Initial focus will be to accelerate development of Vir’s investigational treatments, VIR-7831 and VIR-7832, the companies said.

The companies plan to directly start with a mid-stage trial within the next three to five months.

Experts have said it could take 12 months to 18 months to develop a coronavirus vaccine.

The equity investment from GSK is priced at $37.73 per Vir share, a 10pc premium to the stock’s Friday close.

GSK has so far focused on providing adjuvants, efficacy boosters that play a vital role in many vaccines, as part of its efforts to find potential vaccines against the coronavirus.

This is California-based Vir’s second partnership with a major drugmaker for the development of a potential coronavirus treatment, having last month signed a letter of intent with Biogen Inc.

Must Read

Deputy PM Ishaq Dar reviews integration of ERRA into NDMA

The progress of merging the Earthquake Reconstruction and Rehabilitation Authority (ERRA) with the National Disaster Management Authority (NDMA) was reviewed yesterday by Deputy Prime...